Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also...
| Published in: | Case Reports in Medicine |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2021
|
| Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105366607&doi=10.1155%2f2021%2f5544848&partnerID=40&md5=e86fdd935753af2a2511f99fde408c46 |
| Summary: | Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also used in cases of malignancy-associated hypercalcemia. There are many causes of hypercalcemia, but only rarely it is associated with granulomatous diseases such as tuberculous pleural effusion. We report a case of hypercalcemia from tuberculous pleural effusion that was initially admitted with left medium abundance pleural effusion and a serum corrected calcium level of 3.48 mmol/L. The calcium level was successfully normalized within 72 hours of subcutaneous denosumab administration after other interventions have failed. © 2021 Afdhal Afiq Abd Jalil et al. |
|---|---|
| ISSN: | 16879627 |
| DOI: | 10.1155/2021/5544848 |